Hunan Huateng Pharmaceutical Co., Ltd. (hereafter called Huateng Pharma), founded in August 2013, is a high-tech enterprise dedicated to the research and development and production of high-end biomedical chemical products, as well as the development of precision-targeted anti-tumor drugs. The company develops and produces thousands of products, including monodisperse and polydisperse PEG derivatives, high-end biochemical reagents, pharmaceutical intermediates, APIs, preparations and targeted anti-tumor drugs.
Huateng Pharma is committed to the development, manufacturing, marketing, and distribution of high-end biomedical products to clients worldwide. At present, there are more than 200 employees, among which more than 60% of employees have a master's degree or above, and 35 full-time doctors. Huateng Pharma's R&D center is equipped with high-end analytical instruments and high-end automatic reaction equipment, such as 400M NMR, Agilent LCMS, HPLC, GC, IR, GPC, automatic polarimeter, constant moisture titrator, low-temperature reactor, high-pressure hydrogenation reaction. At present, we have independently developed several thousand kinds of products and have more than 300 invention patents.
Today, Huateng Pharma has an R&D base of 5,000 square meters and a smart pharmaceutical industrial park with an investment of RMB 300 million and an industrial park of 34,000 square meters that has been completed and will be put into operation soon. The park integrates basic technology development, medical research, and achievement transformation. After it is fully put into production, it can achieve annual sales revenue of RMB 1 billion. In addition, Huateng Pharma has established Huateng Pharmaceutical Research Institute to capture cutting-edge industry information and technology, enhance its R&D and production capabilities for high-end generic drugs and innovative drugs, and promote the industrialization of scientific research results.
Huateng Pharma undertook the Sustainable Release Drug R&D International Summit for three consecutive years from 2017 to 2019, and participated in CPHI exhibitions in various countries over the years. In 2019, we received a round A financing of RMB 60 million led by Bo Yi Fund under Tasly, and plan to complete the listing within three years.
Huateng Pharma always insists on technological innovation as its core competitiveness. And the company is committed to providing high-quality pharmaceutical products and services to global customers, and making outstanding contributions to the development of human medicine and health!